Amgen To Pay Hospital $186M Over Royalties

Law360, New York (June 6, 2006, 12:00 AM EDT) -- Amgen Inc. has agreed to pay Massachusetts General Hospital $186 million to resolve a royalty spat over a lucrative drug for arthritis treatment that dragged on for more than a year.

Amgen, based in Thousand Oaks, Calif., has agreed to end future North American royalty payments for Enbrel, which is used to treat rheumatoid arthritis and psoriasis. The hospital will continue to receive royalties from Enbrel sales outside North America.

The drug’s combined royalty brought in nearly 75% of Massachusetts General’s $90 million in licensing fees...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.